Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study

Current Therapeutic Research - Clinical and Experimental

Volumn 67, Issue 4, 2006, Pages 258-269

  Zuo, Xiao Cong ^a,b   Liu, Shi Kun ^b   Yi, Zhi Yong ^c   Xie, Zhi hong ^a   Li, Huan De ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c NONE   (China)

Author keywords

aripiprazole; Chinese; pharmacokinetics; schizophrenic

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CHINA; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DIZZINESS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; ELECTROCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LABORATORY TEST; LOW DRUG DOSE; MALE; MASS SPECTROMETRY; MEAN RESIDENCE TIME; MENTAL HOSPITAL; MULTIPLE DRUG DOSE; MUSCLE WEAKNESS; PHYSICAL EXAMINATION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; SCHIZOPHRENIA; SOMNOLENCE; STEADY STATE; TACHYCARDIA;

EID: 33749267405     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2006.08.003     Document Type: Article

References (20)

1. Abilify (aripiprazole tablets) [prescribing information]. New York, NY: Bristol-Myers Squibb Company; 2004; and Rockville, Md: Otsuka America Pharmaceutical, Inc; 2004. Available at: http://www.abilify.com. Accessed April 15, 2004.
2. Burris K.D., Molski T.F., Xu C., et al. Aripiprazole, a novel antipsychotic, is a highaffinity partial agonist at human dopamine D2 receptors. J Pharrnacol Exp Ther 302 (2002) 381-389
3. 1A receptor. Eur J Pharmacol. 441 (2002) 137-140
4. McQuade R., Burris K.D., Jordan S., et al. Aripiprazole: A dopamine-serotonin system stabilizer. Int J Neuropsychopharmacol 5 Suppl 1 (2002) S176
5. Tamminga C.A. Partial dopamine agonists in the treatment of psychosis. J Neural Transm 109 (2002) 411-420
6. Rush J., et al., American Psychiatric Association. Task Force for the Handbook of Psychiatric Measures. Handbook of Psychiatric Measures. 1st ed (2000), American Psychiatric Association, Washington, DC
7. Kane J.M., Carson W.H., Saha A.R., et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63 (2002) 763-771
8. Potkin S.G., Saha A.R., Kujawa M.J., et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60 (2003) 681-690
9. Pigott T.A., Carson W.H., Saha A.R., et al., Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study. J Clin Psychiatry 64 (2003) 1048-1056
10. Kasper S., Lerman M.N., McQuade R.D., et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 6 (2003) 325-337
11. Shin J.G., Soukhova N., and Flockhart D.A. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6. Drug Metab Dispos. 27 (1999) 1078-1084
12. Mallikaarjun S., Salazar D.E., and Bramer S.L. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 44 (2004) 179-187
13. Auby P., Saha A., Ali M., et al. Safety and tolerability of aripiprazole at doses higher than 30 mg. Eur Neuropsychopharmacol. 12 Suppl 3 (2002) 288
14. Available at:. European Agency for the Evaluation of Medicinal Products. Accessed October 9, 2004. International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6 (2002), WHO, Geneva, Switzerland. http://www.emea.eu.int.
15. Available at:. World Medical Association Declaration of Helsinki. Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects [WMA Web site]. Accessed October 9, 2004 (1989), WMA, Ferney-Voltaire, France. http://www.wma.net.
16. Huang P.C., Yu S.L., Lin Y.M., and Chu C.L. Body weight of Chinese adults by sex, age and body height and criterion of obesity based on body mass index. Nutr Sci J. 17 (1992) 157-172
17. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-1V-TR) (2000), American Psychiatric Association, Washington, DC
18. Kubo M., Mizooku Y., Hirao Y., et al. Development and validation of an LC-MS/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 822 (2005) 294-299
19. Hanmin Z., Xia S., Yuan L.U., et al. Diagnostics of Clinical Experiment (2004), Shanghai Science & Technology Press, Shanghai, China 23-31.
20. Swainston Harrison T., and Perry C.M. Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs 64 (2004) 1715-1736